Herantis Pharma initiates non-invasive CDNF development

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
230
Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki

Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki

Herantis Pharma Plc Company release 6 Jul 2018 at 9:00 am

Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson's disease and potentially other neurodegenerative disorders. In conjunction, Herantis and the University of Helsinki have signed a licensing agreement granting Herantis worldwide, exclusive rights for the therapeutic application of a non-invasive CDNF approach based on a modification of the natural CDNF.

Herantis is currently evaluating natural CDNF in a Phase 1-2 clinical study at three European university hospitals. In the study, CDNF is injected directly into the brain using a delivery system suited for Parkinson's disease patients.  Building on Herantis' drug development expertise, the company will advance also the non-invasive CDNF to translate the new discoveries into clinical programs.

"Non-invasive CDNF is an important expansion to our existing patent estate and strengthens the profile and value of our CDNF program. Our focus as a company is to develop our unique clinical assets for patients in need. Identifying innovative opportunities to improve the technology and expand the application potential is part of our core strategy," said Pekka Simula , Herantis' CEO. "Based on broad and robust preclinical data, we believe CDNF can make a significant difference in the treatment of Parkinson's disease and we look forward to exploring the new possibilities a non-invasive administration could offer to provide the best product for the benefit of patients."

CDNF is a potent neuroprotective factor that promotes neuronal survival. In preclinical proof-of-concept studies CDNF has demonstrated beneficial effects in Parkinson's disease alleviating both motor and non-motor symptoms and stopping disease progression.

"We have previously shown that CDNF protects and recovers neurons from degeneration, neuroinflammation and endoplasmic reticulum stress, critical contributors to many neurodegenerative diseases," explained professor Mart Saarma of the Institute of Biotechnology, HiLIFE, University of Helsinki, a world leading expert in neuronal survival and neurotrophic factor research. "It is exciting to see the progress Pekka and his team have made in translating our findings into an investigational product and bringing it to Parkinson's patients. Our recent discoveries provide an opportunity to target numerous indications beyond Parkinson's with simpler administration and broader distribution while maintaining the full potential of CDNF and I look forward to supporting the company in its development efforts."

Herantis' non-invasive CDNF development program is currently in discovery stage. Target indications for possible future clinical development have not been disclosed.

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445 Company web site: www.herantis.com Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225

About CDNF

CDNF is a novel drug candidate for the treatment of neurodegenerative diseases. Naturally present in the human blood circulation and cerebrospinal fluid, CDNF is a protein with neuroprotective and neurorestorative properties, patented internationally by Herantis. Encouraged by strong preclinical proof-of-concept Herantis has launched a first-in-human, randomized Phase 1-2 clinical study with CDNF in the treatment of Parkinson's disease (PD). The clinical study has received funding from the European Union's research and innovation program Horizon 2020 under grant agreement number 732386.

CDNF administration has been safe in preclinical studies and in first clinical treatments. In disease models, CDNF has protected and regenerated dopamine-generating cells in the midbrain suggesting potential for disease modification of PD. It has also shown efficacy in non-motor symptoms of PD. CDNF drug development is based on research at the Institute of Biotechnology, University of Helsinki, led by professor Mart Saarma . An introductory CDNF video is available on Herantis' website at  http://herantis.com/media/videos/

About drug development in general

Drug development projects can usually be divided in two stages: The preclinical stage, and the clinical stage involving human subjects. The clinical stage can be further broken in three formal phases. Phase 1 clinical studies assess the safety of a drug candidate in human subjects. In Phase 2, the optimal dosing and possible efficacy in the treatment of a particular disease is studied. Phase 3 studies finally aim to establish a statistical proof of safety and efficacy of the drug candidate in typically hundreds or thousands of patients for market approval. Drug development can take 10-15 years from the first preclinical studies to market approval.

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson's disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Nasdaq Helsinki Main media www.herantis.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 0

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 51

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 493

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 326

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 349

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 11

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 187

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 483

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 197

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Integer Holdings Opens Conversion on 2.125% Senior Notes

Updated Category News Views 151

Integer Holdings Announces Conversion of Senior Notes Integer Holdings Corporation (NYSE: ITGR) has recently made headlines with the announcement that its 2.125% Convertible Senior Notes, due in 2028, are now eligible for conversion. This pivotal move allows holders to convert their notes into either cash, common stock, or a combination of both. The option to convert is...

Continue Reading
Investors Urged to Consider Class Action Against Micron Technology

Updated Category News Views 119

Class Action Lawsuit Against Micron Technology, Inc. Levi & Korsinsky, LLP has alerted investors in Micron Technology, Inc. (NASDAQ: MU) regarding an ongoing class action securities lawsuit. This legal action aims to represent those investors who may have incurred financial losses during a specified period. Investors are encouraged to stay informed regarding this...

Continue Reading
Expansion Grant from Bradford White Boosts ECA Internship Program

Updated Category News Views 88

Bradford White Fuels Growth in ECA Internship Program Bradford White Corporation, known for its innovative water heating solutions, has committed $50,000 towards expanding the Energy Coordinating Agency's (ECA) internship program focused on heat pump technology. This initiative aims to enhance training opportunities for the next generation of plumbing and HVAC...

Continue Reading
Industrial Automation Market Set for Significant Growth Ahead

Updated Category News Views 199

Transformations in the Industrial Automation Market Landscape The industrial automation sector is undergoing a major shift as manufacturers worldwide increasingly adopt Industry 4.0 technologies and artificial intelligence. This evolution is spurred by pressing challenges including labor shortages and the need for enhanced operational efficiency. The market is projected...

Continue Reading
Exploring Competitive Landscape of Amazon.com in Retail Sector

Updated Category News Views 159

Understanding Amazon.com's Competitive Position In today's dynamic business world, understanding how companies perform against their competitors is essential. This article delves into a detailed examination of Amazon.com (NASDAQ: AMZN) and compares it with key rivals in the broadline retail sector. By exploring crucial financial data, market strategies, and growth...

Continue Reading